Azeliragon is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as an oral small-molecule inhibitor of the receptor for advanced glycation end products (RAGE), which is implicated in the inflammatory processes and amyloid-beta accumulation associated with Alzheimer's. By blocking RAGE, azeliragon aims to reduce neuroinflammation and slow disease progression. Clinical trials have explored its efficacy in improving cognitive function and delaying cognitive decline in patients with mild Alzheimer's. Additionally, its anti-inflammatory properties are being studied for potential applications in other conditions involving chronic inflammation or RAGE-mediated pathways, such as diabetes and certain cancers. However, further research is needed to fully establish its clinical benefits and safety profile.